金活醫藥集團(01110.HK)盈喜:預計中期溢利增加約35%至40%
格隆匯8月2日丨金活醫藥集團(01110.HK)公佈,公司預計截至2023年6月30日止六個月溢利將較上年同期溢利人民幣35.1百萬元增加約35%至40%。
董事會認為集團溢利增加主要是由於隨着針對新型冠狀病毒(COVID-19)疫情的管控措施取消,使市場在期間相對前期間有所復甦,致(i)從事品牌進口醫藥及保健產品的中國分銷業務的收益及毛利分別增加約30%至35%及15%至20%;及(ii)應占一家合營企業溢利增加約55%至60%所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.